CD274 and cardiovascular disorder: Our study identified 27,820 patients with pre‐existing cardiovascular disease who received anti‐PD‐1 or anti‐PD‐L1 therapy for malignant neoplasms of the bronchus and lung, digestive organs, urinary tract, or skin and an equal number of matched controls (n = 27,820).